Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes

Authors

  • Hanne Skjerven Bersvendsen Department of Oncology, University Hospital of North Norway, Tromsø, Norway;  Department of Clinical Medicine, UIT-The Arctic University of Norway, Tromsø, Norway
  • Hege Sagstuen Haugnes Department of Oncology, University Hospital of North Norway, Tromsø, Norway;  Department of Clinical Medicine, UIT-The Arctic University of Norway, Tromsø, Norway
  • Unn-Merete Fagerli Department of Oncology, St. Olav’s Hospital, Trondheim, Norway;  Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
  • Øystein Fluge Department of Oncology, Haukeland University Hospital, Bergen, Norway
  • Harald Holte Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway;  K.G. Jebsen-Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  • Knut Bjøro Smeland Department of Oncology, National Advisory Unit for Late Effects After Cancer, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
  • Tom Wilsgaard Department of Community Medicine, UIT-The Arctic University of Norway, Tromsø, Norway
  • Cecilie Essholt Kiserud Department of Oncology, National Advisory Unit for Late Effects After Cancer, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

DOI:

https://doi.org/10.1080/0284186X.2018.1558370

Abstract

Introduction: High-dose therapy with autologous stem cell transplantation (HD-ASCT) is associated with an increased risk of late effects. Our aim was to assess lifestyle behavior and factors associated with unhealthy lifestyle among HD-ASCT-treated lymphoma survivors (HD-ASCT-LS).

Materials and methods: We conducted a national cross-sectional study of HD-ASCT-LS treated during 1987–2008. Among 399 eligible participants, 312 (78%) completed patient-reported outcome measures (PROMs) on lifestyle behavior (physical activity, overweight, smoking and alcohol consumption), chronic fatigue (CF) and somatic and mental illness. We assessed lifestyle according to WHO recommendations. Multivariable logistic regression models were used to study associations between variables. A comparison to the general population was performed.

Results: Mean age at survey was 54.6 years, 60% were men, 55% sedentary, 55% overweight, 18% smokers and 5% had unhealthy alcohol consumption. Being sedentary was positively associated with older age, low household income, CF and higher somatic burden (≥4 self-reported somatic conditions). Overweight was positively associated with male gender and negatively associated with increased number of chemotherapy regimens prior to HD-ASCT. Current smoking was positively associated with living alone and CF, and negatively associated with older age. Male gender, CF and higher somatic burden increased the risk of an unhealthier lifestyle whereas the increased number of chemotherapy regimens prior to HD-ASCT decreased the risk. HD-ASCT-LS were significantly less sedentary, less overweight, and had a lower likelihood of smoking than the controls.

Discussion: Assessed by PROMs, unhealthy habits were frequent among HD-ASCT-LS and associated with comorbidity. Nevertheless, compared with controls significantly more HD-ASCT-LS met lifestyle recommendations. These results indicate that the HD-ASCT-LS may consist of two groups, the adhering group with less comorbidity and the non-adhering group with more comorbidity. Our findings illustrate the necessity of recommendations and support for improving health-related behavior in cancer survivorship plans in order to empower survivors in their life beyond cancer.

Downloads

Download data is not yet available.

Downloads

Published

2019-05-04

How to Cite

Skjerven Bersvendsen, H., Sagstuen Haugnes, H., Fagerli, U.-M., Fluge, Øystein, Holte, H., Bjøro Smeland, K., Wilsgaard, T., & Essholt Kiserud, C. (2019). Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes. Acta Oncologica, 58(5), 690–699. https://doi.org/10.1080/0284186X.2018.1558370